IMW 2019 | Predicting MM progression
Mark Bustoros
• 12 Sep 2019
Mark Bustoros, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses how the use of genomic predictors in multiple myeloma (MM) allows for the greater stratification of patients and thus provides clinicians with an increased capacity to predict who is most likely to progress. This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.
